Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.

[1]  M. Levine,et al.  Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines , 2014, Clinical and Vaccine Immunology.

[2]  A. Kantele,et al.  Cross‐Reactive Immune Response Induced by the Vi Capsular Polysaccharide Typhoid Vaccine Against Salmonella Paratyphi Strains , 2014, Scandinavian journal of immunology.

[3]  A. Kantele,et al.  Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae. , 2014, Vaccine.

[4]  M. Levine,et al.  Live Oral Salmonella enterica Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React with S. Paratyphi A and S. Paratyphi B , 2014, Clinical and Vaccine Immunology.

[5]  Estela Trebicka,et al.  Role of Antilipopolysaccharide Antibodies in Serum Bactericidal Activity against Salmonella enterica Serovar Typhimurium in Healthy Adults and Children in the United States , 2013, Clinical and Vaccine Immunology.

[6]  M. Levine,et al.  Invasive nontyphoidal Salmonella disease in Africa: current status , 2013, Expert review of anti-infective therapy.

[7]  A. Kantele,et al.  Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines–A Randomized Trial , 2013, PloS one.

[8]  A. Siitonen,et al.  Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella? , 2012, Vaccine.

[9]  A. Kantele,et al.  Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. , 2012, Vaccine.

[10]  Nicholas A Feasey,et al.  Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa , 2012, The Lancet.

[11]  M. Levine,et al.  Live Oral Typhoid Vaccine Ty21a Induces Cross-Reactive Humoral Immune Responses against Salmonella enterica Serovar Paratyphi A and S. Paratyphi B in Humans , 2012, Clinical and Vaccine Immunology.

[12]  C. Mannella,et al.  Association of a Protective Monoclonal IgA with the O Antigen of Salmonella enterica Serovar Typhimurium Impacts Type 3 Secretion and Outer Membrane Integrity , 2012, Infection and Immunity.

[13]  O. Levine,et al.  Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. , 2012, American journal of public health.

[14]  J. Clemens,et al.  Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. , 2010, Bulletin of the World Health Organization.

[15]  J. Sirard,et al.  The Microbiota Mediates Pathogen Clearance from the Gut Lumen after Non-Typhoidal Salmonella Diarrhea , 2010, PLoS pathogens.

[16]  Aamir Fazil,et al.  The global burden of nontyphoidal Salmonella gastroenteritis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Levine,et al.  Identification by PCR of Non-typhoidal Salmonella enterica Serovars Associated with Invasive Infections among Febrile Patients in Mali , 2010, PLoS neglected tropical diseases.

[18]  A. Lundgren,et al.  Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. , 2009, Vaccine.

[19]  N. Mantis,et al.  Inhibition of Salmonella enterica Serovar Typhimurium Motility and Entry into Epithelial Cells by a Protective Antilipopolysaccharide Monoclonal Immunoglobulin A Antibody , 2008, Infection and Immunity.

[20]  G. Dougan,et al.  The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. , 2008, The Journal of clinical investigation.

[21]  J. Mora,et al.  Differentiation and homing of IgA-secreting cells , 2008, Mucosal Immunology.

[22]  L. Leibovici,et al.  Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. , 2007, Vaccine.

[23]  Ivan S F Chan,et al.  Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older , 2007, Journal of the American Geriatrics Society.

[24]  Rosanna Lagos,et al.  Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  D. Favre,et al.  Vaccines against typhoid fever. , 2006, Vaccine.

[26]  Eli Schwartz,et al.  Enteric fever in Israeli travelers: a nationwide study. , 2006, Journal of travel medicine.

[27]  A. Kantele,et al.  Unique characteristics of the intestinal immune system as an inductive site after antigen reencounter. , 2005, The Journal of infectious diseases.

[28]  J. Crump,et al.  The global burden of typhoid fever. , 2004, Bulletin of the World Health Organization.

[29]  J. Lau,et al.  Vaccines for preventing typhoid fever , 2018, The Cochrane database of systematic reviews.

[30]  E. Butcher,et al.  Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.

[31]  E. Butcher,et al.  Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. , 1997, Journal of immunology.

[32]  A. Kantele,et al.  Circulating immunoglobulin‐secreting cells are heterogeneous in their expression of maturation markers and homing receptors , 1996, Clinical and experimental immunology.

[33]  S. Jalkanen,et al.  Mucosally activated circulating human B cells in diarrhea express homing receptors directing them back to the gut. , 1996, Gastroenterology.

[34]  A. Blum,et al.  Monoclonal immunoglobulin A prevents adherence and invasion of polarized epithelial cell monolayers by Salmonella typhimurium. , 1994, Gastroenterology.

[35]  E. Berg,et al.  α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 , 1993, Cell.

[36]  A. Fattorossi,et al.  Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. , 1993, Vaccine.

[37]  J. Mekalanos,et al.  Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium , 1992, Infection and immunity.

[38]  L. Picker,et al.  ELAM-1 is an adhesion molecule for skin-homing T cells , 1991, Nature.

[39]  A. Kantele,et al.  Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. , 1991, Microbial pathogenesis.

[40]  A. Kantele.  Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. , 1990, Vaccine.

[41]  I. Stamenkovic,et al.  Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor , 1989, Nature.

[42]  M. Levine,et al.  Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. , 1989, The Journal of infectious diseases.

[43]  P. Matricardi,et al.  Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines , 1988, Infection and immunity.

[44]  R. Black,et al.  LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATION , 1987, The Lancet.

[45]  L. Nencioni,et al.  IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. , 1986, Journal of immunology.

[46]  M. Levine,et al.  Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. , 1986, The Journal of infectious diseases.

[47]  S. Michalek,et al.  Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. , 1984, Journal of Immunology.

[48]  O. Mäkelä,et al.  Isotype of protective anti-Salmonella antibodies in experimental mouse salmonellosis , 1984, Infection and immunity.

[49]  Efsa Journal,et al.  European Food Safety Authority, European Centre for Disease Prevention and Control; The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2009 , 2011 .